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Background: Recent increases in genomic studies of the developing human fetus and neonate have led to a need
for widespread characterization of the functional roles of genes at different developmental stages. The Gene
Ontology (GO), a valuable and widely-used resource for characterizing gene function, offers perhaps the most
suitable functional annotation system for this purpose. However, due in part to the difficulty of studying molecular
genetic effects in humans, even the current collection of comprehensive GO annotations for human genes and
gene products often lacks adequate developmental context for scientists wishing to study gene function in the
human fetus.
Description: The Developmental FunctionaL Annotation at Tufts (DFLAT) project aims to improve the quality of
analyses of fetal gene expression and regulation by curating human fetal gene functions using both manual and
semi-automated GO procedures. Eligible annotations are then contributed to the GO database and included in GO
releases of human data. DFLAT has produced a considerable body of functional annotation that we demonstrate
provides valuable information about developmental genomics. A collection of gene sets (genes implicated in the
same function or biological process), made by combining existing GO annotations with the 13,344 new DFLAT
annotations, is available for use in novel analyses. Gene set analyses of expression in several data sets, including
amniotic fluid RNA from fetuses with trisomies 21 and 18, umbilical cord blood, and blood from newborns with
bronchopulmonary dysplasia, were conducted both with and without the DFLAT annotation.
Conclusions: Functional analysis of expression data using the DFLAT annotation increases the number of
implicated gene sets, reflecting the DFLAT’s improved representation of current knowledge. Blinded literature
review supports the validity of newly significant findings obtained with the DFLAT annotations. Newly implicated
significant gene sets also suggest specific hypotheses for future research. Overall, the DFLAT project contributes
new functional annotation and gene sets likely to enhance our ability to interpret genomic studies of human fetal
and neonatal development.
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A growing awareness of developmental impacts on life-
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reproduction in any medium, provided the oraffect the fetus and neonate. In the past, biologists relied
on analyses of cultured cells or animal models to under-
stand human development. Now, gene expression data
sets derived from the human placenta [3], cell-free RNA
in amniotic fluid [4,5], or the blood of pregnant women
[6] are increasingly being made available. Correctly
interpreting such data is important, because it is only a
matter of time before sequence, expression, and clinical
data are integrated to provide a comprehensive view of
development that influences clinical decisions.
Our ability to understand and interpret such high-
throughput molecular data, however, depends heavily ond. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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long influenced the analysis of gene expression data [8,9]
and is relevant to the interpretation of sequence variation
as well [10]. Most commonly, functional annotation data-
bases, in which genes or gene products are linked to par-
ticular molecular, biological, or other functional processes,
are scanned to find annotation categories that are statisti-
cally overrepresented in the set of implicated genes. In
addition to post hoc analyses of functional categories over-
represented in lists of individually-implicated genes, it has
become commonplace to use pre-defined gene sets as a
group to identify the implicated pathways [11-15]. For
example, a gene set implicated in the process of “single
strand break repair” might consist of the genes APLF,
APTX, LIG4, SIRT1, TDP1, and TNP1. Even if none of
these genes is itself significantly upregulated in a set of
phenotypically related samples, if all of the genes are mo-
derately upregulated, the consistency of those changes
might indicate that the process is indeed upregulated in
the phenotype. Such gene-set analysis methods can be
highly effective, but only if the functional annotation used
to create the gene sets is informative about the specific
conditions being studied [16].
There are several sources of functional pathway anno-
tation used for this purpose. The most frequently refer-
enced annotation source is the Gene Ontology (GO)
[17], a collaborative effort to standardize the functional
annotation of genes and gene products using a con-
trolled vocabulary of terms connected by relationships
that result in directed, acyclic graphs. The application of
this vocabulary allows broad inferences to be made
based on the grouping of many isolated annotations.
Community participation and shared standards encour-
age consistent annotation across a wide range of species.
GO annotations, linked to their supporting evidence in
the primary literature, are publicly available and broadly
relevant to a range of fields. Although not initially de-
signed explicitly for this purpose, annotation from the
GO is often used for gene set analysis [11,18-20].
The Gene Ontology’s framework for representing deve-
lopmental processes is quite detailed [21,22]. However, ne-
cessarily, much of the human genetic information in the
GO database is derived from research conducted on adult
subjects or in cultured cells. Other annotations linking
genes to human developmental processes are derived from
studies of embryonic development in invertebrate model
organisms such as C. elegans or D. melanogaster. Many of
these genes do indeed have human orthologs with similar
functions, especially in the realms of cell polarity, neuro-
logical development, and immunity [23]. However, other
human developmental processes, particularly those crucial
in later stages of development, are not as well modeled in
these organisms as they are in vertebrates such as M.
musculus [24,25]. Molecular developmental annotationin mouse is substantial [22,26,27], but it has not yet
systematically been leveraged to extend the human devel-
opmental annotation in GO. Thus, functional analyses in
humans can lead to results that are insufficiently inform-
ative about the normal physiological changes occurring in
the developing fetus.
Here, we describe our efforts to address this limitation
through a project entitled “Developmental FunctionaL
Annotation at Tufts” (DFLAT). The goal of the DFLAT
project is to improve our understanding of human fetal
development by adding appropriate human-specific, de-
velopmentally-relevant annotation to the Gene Ontology
(GO) database and by maintaining a collection of gene sets
tailored for use in studying human development. The next
section of the manuscript, Construction and content, de-
scribes the methods used to derive the DFLAT annotation
and gene sets.
We then assess the impact of the DFLAT annotation.
Functional annotation can be used in many ways, but
one common application is for functional analyses of
high-throughput molecular data. In the section Utility
and discussion, we describe a case study in which we use
Biological Process gene sets derived from DFLAT-
augmented GO annotation to analyze data from several
previously published gene expression microarray experi-
ments. Comparison of the analytical results to those de-
rived from existing annotation demonstrates that using
the annotation and gene sets provided by DFLAT allows
researchers to more accurately perform gene set and
pathway enrichment analyses when studying human
development.
Construction and content
Annotation: curation and inference
Annotation related to human development was manually
collected from the literature by DFLAT curators using
the Protein2GO curation tool [28] and the methodology
of the Gene Ontology Consortium [29]. Annotation ef-
forts were focused particularly on genes relating to de-
velopmental and biological processes that neonatologists
considered likely to be detected in fetal expression data
obtained during the second and third trimesters, inclu-
ding heart, lung, and brain development. Eligible anno-
tations were submitted to the Gene Ontology directly
through Protein2GO and included in subsequent data
releases [30].
In examining the literature, curators often found that
functional information as presented in some papers did
not quite meet the current standards for human GO cur-
ation. For example, a paper might refer to a gene product
in a vague way that could be mapped to two or more dif-
ferent UniProt IDs, or the relevant sentence might require
a TAS (Traceable Author Statement) evidence code, which
is not considered sufficiently strong evidence for human
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traced back to the original experimental data. (For ex-
ample, GONE links the gene LGI1 and the GO term
“hippocampus development” (GO:0021766) with a TAS
evidence code. This annotation was derived from a sen-
tence in one paper [31] that refers to another paper’s evi-
dence about LG1’s role in synapse maturation in the
hippocampus).
Such annotations can nonetheless be valuable in the ag-
gregate for use by gene set analysis methods, which are
designed to find significant patterns across multiple genes
and are therefore easily able to handle a slightly higher
noise rate in gene set membership. These annotations
were stored in a separate collection, described as “Gene
Ontology Non-Eligible” (GONE). DFLAT curators have so
far submitted 613 manually-curated annotations to GO
and 664 to GONE. Both sets of annotation are available
on the DFLAT website (http://dflat.cs.tufts.edu).
Because of the slow pace of manual curation, we were
interested in determining whether the judicious use of
mammalian orthology might provide a fast yet accurate
way to augment the human developmental annotation.
Automated orthology-mapping of annotation was per-
formed using one-to-one mouse-to-human orthologs
taken from the Mouse Genome Informatics (MGI) data-
base (orthology assertion as defined by Homologene [32]).Figure 1 Overview of sources of DFLAT annotation. On the left-hand s
for manual curation of the literature, which proceeds according to the me
submitted to the Gene Ontology and included in subsequent data release
collection. The right-hand side of the image depicts our procedure for de
identified by having GO annotations in the “Developmental Process” subt
orthologs, all mouse annotations with the required evidence codes are mOnly annotations within the developmental branch of the
GO were used to transfer annotations between species.
Mapping was limited to annotations with experimental
evidence codes (EXP, IDA, IPI, IMP, IGI, and IEP).
Evidence codes indicating annotation derived from com-
putational analyses, including ISS and its children, were
removed to avoid generalizing annotations that might
have originally been derived through orthology. Automa-
tically assigned, author statements, and curator statements
were also excluded. A similar approach is standard in the
Mouse Genome Informatics’ Gene Ontology annotation
pipeline.
In total, 12,798 unique orthologous annotations were
derived from this approach. An overview of the different
sources of data in DFLAT appears in Figure 1.
We note that this use of orthologs affects our ability to
focus on a specific developmental stage. Annotations to
GO terms that are descendants of the term “Developmental
Process” are not necessarily limited to fetal or even pre-
natal development. Furthermore, while there have been at-
tempts to broadly align developmental stages in mouse
and human (e.g., [33]), developmental processes in specific
organs or systems may take place at very different times
from those predicted by such alignment [34], with some
processes that are completed in the human fetus conti-
nuing postnatally in the mouse (and vice-versa). (E.g., theide, neonatologists suggest keywords and developmental processes
thodology of the Gene Ontology Consortium. Eligible annotations are
s. Others, valuable for our purposes, become part of the “GONE”
riving annotation from mouse orthologs. Mouse genes of interest are
ree. For those genes for which MGI has identified unique human
apped to the corresponding human gene.
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and the development of some perceptual systems is much
further along in neonatal humans than in mice [35]. For
example, the onset of hearing in the mouse develops du-
ring the second postnatal week, with the maturation of
the organ of Corti [36], while in the human this occurs
prenatally by approximately the 24th week of gestation
[37]). Thus, by including orthology-derived annotation,
we are using a wide brush, potentially including informa-
tion about not only fetal but also neonatal and perhaps
subsequent developmental processes. Some implications
of this decision are discussed in the section Utility and
discussion, below.
Construction of DFLAT gene sets
Manually curated GO and GONE annotations, the
ortholog-derived annotations described above, and hu-
man Gene Ontology Annotation (GOA) (downloaded 4/
10/13) were collected in a single GAF 2.0 annotation file.
Gene Symbols were derived from UniProt IDs (using the
mapping at http://www.uniprot.org/). Annotations iden-
tified in more than one group (such as manually-curated
and orthology-derived annotations) were consolidated.
In total, 13,344 unique DFLAT annotations were com-
bined with the existing Gene Ontology data.
We then used this full annotation collection to create
GMT-formatted gene sets (http://www.broadinstitute.org/
cancer/software/gsea/wiki/index.php/Data_formats) for useFigure 2 Propagation of Gene Ontology annotation. Genes or gene pr
GO annotation term to all of its parents via is_a (solid arrows) and part_of
products directly annotated to the GO term; the remaining letters indicatein Gene Set Enrichment Analysis. This simple text file for-
mat is readily convertible for use with other gene set ana-
lysis methods.
In an effort to maximize consistency with the GO-
derived collection of gene sets (known as “C5”) in GSEA’s
Molecular Signature database [38], we used only GO and
GONE annotations with the evidence codes IDA, IPI,
IMP, IGI, IEP, ISS, or TAS in the formation of our
gene sets (http://www.broadinstitute.org/gsea/msigdb/
collection_details.jsp). All orthologous annotations were
included as well. Annotations with the NOT qualifier were
excluded. Our gene set collection and the C5 collection
both consist of gene sets corresponding to GO terms, with
each gene set containing the human genes annotated with
that particular term.
To reflect the propagation of annotation terms
through the Gene Ontology, and for further consistency
with the C5 collection, gene annotations were propa-
gated to all ancestors of the original annotated GO
term (Figure 2). For this purpose, ancestors were deter-
mined by is_a and part_of relationships, as defined in
the gene_ontology_ext.obo file (downloaded 4/10/13).
DFLAT’s developmentally-focused human gene sets, as
well as the scripts used to create them, are freely avail-
able on the DFLAT website (http://dflat.cs.tufts.edu).
Despite our efforts to match the methods used in the
construction of the C5 collection, unavoidable differences
in the GOA source data (based on date of download) andoducts (letters A-P) are propagated up the GO graph from the original
(dashed arrows) relationships. Bold text letters indicate genes or gene
propagated annotations.
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process made it impossible to evaluate the impact of the
new annotation by direct comparison to C5. Accordingly,
for the purpose of comparison, we also created a collec-
tion of gene sets using the same methods used to create
the DFLAT gene sets described above, but containing only
the downloaded GOA data. These “GOA-only” gene sets
are also available on our web site. Gene sets with fewer
than 7 genes are generally considered too small to be used
in gene set analysis [11], although we included the smaller
gene sets in our data release for completeness. Compared
to these “GOA-only” gene sets, the Biological Process
gene set collection created with the additional DFLAT
annotation included 381 additional GO terms whose cor-
responding gene sets contain at least 7 genes (and a total
of 476 additional GO terms of any size).
Utility and discussion
DFLAT’s primary purpose is to enable the study of human
development through gene-set or pathway-based analyses
of high throughput expression data. We hypothesized that
the collection of additional annotation tailored to fetal and
neonatal developmental stages would result in more bio-
logically relevant and accurate results in the analysis of ex-
pression data from patients in these age groups than
would be obtained using existing functional annotation.
To demonstrate DFLAT’s impact, we therefore used gene
set enrichment analysis (GSEA) to analyze five gene ex-
pression data sets with the GOA-only gene set collection
and, separately, with the DFLAT-augmented gene set col-
lection. The results of this comparative analysis de-
monstrate that DFLAT is serving its intended role by
improving our functional analyses of fetal, neonatal, and
even later developmental expression data.
Data and methods for comparison of DFLAT and
GOA-only analyses
The data sets include two studies of cell-free mRNA gene
expression in amniotic fluid of aneuploid fetuses compared
to euploid controls. The first study identified patterns of
oxidative stress and its consequences in second-trimester
trisomy 21 fetuses compared to age- and sex-matched
controls [39]. The second characterized the differences
between second-trimester amniotic fluid in trisomy 18 fe-
tuses and euploid controls [40], implicating ion transport,
immunity, glycosylation, and G-protein mediated signaling
pathways. The third data set comes from a paper demon-
strating the possibility of identifying cell-free fetal RNA in
maternal blood taken shortly before full-term elective
cesarean deliveries [6]. The fourth data set characterizes
complications of prematurity in expression patterns of
blood samples drawn from neonates born below 1500 g
and before 32 weeks’ gestational age [41]. From this com-
plex data set, we focused on the long-term respiratorycomplication of prematurity, bronchopulmonary dysplasia
(BPD). We selected just the samples taken on approxi-
mately the 14th postnatal day (time point B, corresponding
to subjects still below 34 weeks’ gestational age) and cate-
gorized them as either having BPD (including mild, mo-
derate, and severe cases as indicated by the authors) or
not. The final data set compared acute megakaryoblastic
leukemia in patients with and without Down syndrome
[42]. Because the DFLAT annotation is focused on fetal
development, we hypothesized that its impact would be
greatest on gene expression data from very young subjects.
Yet few of the samples are truly neonatal. Accordingly, we
selected from the leukemia data set only those samples
from subjects younger than 24 months. We refer to these
five data sets in the tables below as “trisomy 21”, “trisomy
18”, “maternal/fetal blood”, “BPD”, and “leukemia”, re-
spectively. Further details about the data sets, including
their Gene Expression Omnibus (GEO) IDs, appear in
Additional file 1: Table S1. Each data set was normalized
using the method described in the associated GEO record.
For all analyses, we wrote scripts to run the java im-
plementation of GSEA (version 2–2.07) [11] in batch
mode. In all cases but one, the analysis was a straightfor-
ward comparison of two classes, and the normalized
data sets were provided as input to GSEA. The excep-
tion was the maternal/fetal blood data set. Because this
analysis results from a more complex comparison that is
not easily expressed as a simple binary classification
problem, we instead ran a GSEA “pre-ranked” analysis.
For this analysis, microarray qualifiers were ranked by
the log of the maximum p-value from one of two com-
parisons: antepartum maternal blood compared to post-
partum maternal blood from the same mother, and
antepartum maternal blood compared to umbilical cord
blood from each mother and her baby [6]. The genes
with the most extreme negative ranks are those that are
most significantly up-regulated in antepartum maternal
blood compared to both postpartum maternal blood and
cord blood, and are thus potentially fetal in origin.
The most meaningful measurement of gene set enrich-
ment is often the false discovery rate (FDR) q-value, which
GSEA derives through permutation. However, for several
reasons, we will discuss only the raw p-values here. First,
it is difficult to compare false-discovery rates fairly bet-
ween gene set collections containing different numbers of
gene sets. In addition, some of the data sets, particularly
the trisomy 18 study, contain relatively few samples in
each class. Most gene sets in such experiments have
q-values of 1.0 for both gene set collections, but their
p-values still provide evidence about the differences bet-
ween the two gene set collections. Finally, adjusting for
multiple testing between highly-overlapping gene sets
such as those derived from the Gene Ontology is a fraught
process to begin with, and such adjustment methods
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Yet this overlap structure also differs between the collec-
tions. For the purposes of evaluating the differences bet-
ween the two collections, therefore, we have chosen to
focus exclusively on the unadjusted p-values reported by
GSEA.
Gene set availability increases with DFLAT
In gene set enrichment analysis (GSEA), the gene sets
considered for each analysis are typically selected based
on the gene set sizes (i.e., the number of genes in each
gene set that are included in the input gene expression
data). We chose to require a minimum of 7 genes and a
maximum of 150 genes for all gene sets in the analyses
described here, because with fewer than about 7 genes
the permutation analyses to assess significance lack suffi-
cient granularity [11], and because gene sets larger than
approximately 150 genes tend to be high-level, broad
categories that are not very informative. DFLAT contains
more annotations than GOA, increasing the number of
genes in many of the gene sets. As a result, using the
DFLAT collection allows some gene sets to grow large
enough to meet the minimum size threshold in GSEA.
We call these newly-included gene sets “unique to
DFLAT”. However, other, larger gene sets may grow in
size enough to be disqualified; we call these “unique to
GOA”.
One important question is therefore to evaluate the tra-
deoff between the gene sets gained and those lost in the
DFLAT analysis. In all five studies, we find more gene sets
unique to DFLAT than unique to GOA (Table 1). The
total number of gene sets meeting these size criteria, for
DFLAT/GOA respectively, is 3,700/3,358 for the three
data sets on Affymetrix U133 Plus 2.0 arrays (Trisomy 21,
Trisomy 18, and BPD); 3,563/3,245 for the Maternal/Fetal
Blood data set on U133A arrays, and 3,649/3,332 for the
Leukemia data set (where the published data in GEO
mapped the qualifiers on the U133A arrays to gene
symbols). Even if we restrict our attention to the most
significantly-changing gene sets, those with p-values below
0.05 (Table 1, center and right-hand columns), we see thatTable 1 Numbers of unique gene sets
Total Si
Study DFLAT GOA D
Trisomy 21 406 64 14
Trisomy 18 406 64 22
Maternal/fetal blood 376 58 14
BPD 406 64 23
Leukemia 372 55 44
Unique gene sets are gene sets that meet the GSEA size filter (7–150 genes) in only
*Because of the design of this study, these numbers report significant changes in o
expression in maternal blood. If we count significant changes in both directions, we
that likely characterize maternal response to Cesarean delivery, rather than fetal expDFLAT is contributing more significantly-implicated gene
sets to the results than it is taking away.
The annotation we have added is intentionally func-
tionally-biased, augmenting some categories more than
others. Previous work has demonstrated that despite this
bias, such functionally-focused annotation efforts can
have a positive impact on the outcome of downstream
analyses [45]. We contend that having larger numbers of
gene sets available for analysis is likely to have a similar
positive effect, because functionally-coherent differential
expression can only be detected if the relevant gene sets
are considered [16]. The primary lesson from Table 1 is
that by adding focused annotation, we have increased
the number of available gene sets. The resulting analyses
indeed show a corresponding increase in the number of
gene sets significantly implicated in the differential ex-
pression analyses.
Table 1 does not, however, suggest that the gene sets
unique to DFLAT are more likely to be significantly
enriched than their unique-to-GOA counterparts. By a
one-sided Fisher’s exact test, there is no evidence that the
fraction of unique DFLAT gene sets that are significant at
the .05 level is larger than the fraction of GOA gene sets
that are significant at the .05 level, except in the BPD data
set (p-value < 0.038). And in fact, the leukemia data set
shows a significant difference (p-value < 0.01) in the other
direction. Possibly this is due to the fact that it is the only
one of these data sets including subjects beyond the fetal
and neonatal developmental stages targeted in the DFLAT
curation process. But even if the number of significant
gene sets is roughly proportional to the number of gene
sets considered, as long as the user’s false discovery rate
cutoff remains the same, an increase in the number of
gene sets will likely translate to a larger number of correct
discoveries.
The addition of DFLAT annotation caused widespread
changes in gene set membership. Therefore, the results
of GSEA differential expression analyses across all five
studies change substantially. We can compare these re-
sults further by looking at the gene sets that meet the
size criteria for inclusion under both gene set collectionsgnificant (p < 0.05) % significant
FLAT GOA DFLAT GOA
2 3.45 3.13
3 5.42 4.69
* 2* 3.72* 3.45*
0 5.67 0.00
16 11.83 29.10
one of the two gene set collections, DFLAT or GOA.
nly one direction – gene sets that might be characterizing fetal gene
find 38 and 6 with DFLAT and GOA, respectively, but these include functions
ression.
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call these the “common” gene sets. Among common gene
sets, the use of the DFLAT collection changed the re-
ported raw p-values in nearly all of them. If we again focus
just on those gene sets that are most enriched (those with
p-values < 0.05 in either study), we still find that nearly all
of them (91.4-99.5%) change in significance (data not
shown). In most of the studies, about half of the gene sets
common to both collections showed increased signifi-
cance using DFLAT, and about half showed increased sig-
nificance using the GOA-only collection.
When we consider all gene sets together (both com-
mon and unique), we find that by incorporating the
DFLAT annotation, we typically gain more gene sets
meeting a particular significance cutoff (e.g., in Table 2,
p < 0.05) than we lose. Of course, drawing a hard line to
indicate significance is somewhat arbitrary and problem-
atic, but such cutoffs at least indicate that the additional
annotation is expanding the number of enriched GO
terms detected at a particular threshold.
These results appear encouraging. However, it is diffi-
cult to evaluate them properly without knowing which
gene sets should be enriched in each analysis. This is a
much more difficult problem, which we now address.
Literature verification supports DFLAT’s new
contributions
The best representation of the current state of biomed-
ical knowledge on a particular topic is the collection of
relevant published literature. Indeed, this is the source
of the Gene Ontology annotation in the first place; it is
just that the labor-intensive annotation effort required
and the accelerating pace of publication means that
there is a substantial amount of information in the lit-
erature that has not yet been incorporated into GO.
We therefore attempted to partly assess the accuracy
of annotation terms that have changed in “status” (i.e.,
crossed some significance cutoff ) between the DFLAT
and GOA-only analyses by reviewing the literature toTable 2 Total number newly significant/insignificant
(p < 0.05) gene sets with DFLAT
Study Newly significant Newly insignificant
Trisomy 21 47 29
Trisomy 18 37 16
Maternal/fetal blood* 22 6
BPD 50 27
Leukemia 108 49
Total number of gene sets (either “unique” or “common”) showing enrichment
(GSEA p < 0.05) with only the DFLAT collection (“Newly significant”) or the
GOA collection (“Newly insignificant”).
*Because of the design of this study, these numbers report the significant
changes only in the meaningful direction: gene sets that might characterize
fetal gene expression in maternal blood. Changes in the other direction likely
characterize maternal response to Cesarean delivery.find corroborative experimental evidence for such terms.
Because this validation process is also labor-intensive,
we performed this analysis only for the trisomy 21 and
trisomy 18 studies (chosen because the phenotypes
under investigation are relatively clear and well repre-
sented in the literature). Published evidence was sought
linking the gene sets significantly enriched under only
one annotation collection, tallied in Table 2, to the indi-
cated aneuploidy. In order to eliminate bias, the team
members performing the literature review were blinded
to whether each listed gene set was significantly impli-
cated in the DFLAT or the GOA-only analysis.
Each term was considered in the context of the indi-
cated trisomy, and was assigned to one of two categories:
either the indicated function was supported by a report in
the literature, or no evidence about that function was
found. A full list of the terms considered and the suppor-
ting references identified is available in Additional file 2:
Table S2.
Our results, shown in Tables 3 (trisomy 21) and 4 (tri-
somy 18), indicate that GSEA analysis with DFLAT pro-
duces more newly-significant biological process terms
whose relevance to the indicated trisomy is supported by
publications than GSEA analysis of the same data using
the GOA-only collection. The tables show the percen-
tage (and numbers, in parentheses) of terms identified as
significant with the indicated gene set collection that
had literature support. Although we cannot easily de-
termine the significance of the differences reported in
Tables 3 and 4, both the trend and the science behind
the implicated gene sets are consistent with the hypo-
thesis that the additional DFLAT annotation provides
new and valuable information about the data sets being
analyzed.
A closer look at specific gene sets identified in the tri-
somy 21 analyses gives insight into what new information
DFLAT is providing or culling. Several gene sets that reach
the 0.05 significance cut off in the GOA-only analysis are
vague umbrella terms that provide little specific insight
into trisomy 21, such as Axis specification, Determination
of left/right symmetry, and Modified amino acid transport.
None of these broad processes was directly linked to tri-
somy 21 in the literature. Instead, the enriched terms
enriched from the DFLAT collection implicate a diverse
spectrum of organ systems affected by trisomy 21, inclu-
ding the nervous system (Cranial nerve morphogenesis,
Myelin, Cerebellum development, Midbrain development,Table 3 Verified gene set significance (p < 0.05) in
Trisomy 21
Gene set Supported by literature No evidence
DFLAT 85.1% (40) 14.9% (7)
GOA 65.5% (19) 34.5% (10)
Table 4 Verified gene set significance (p < 0.05) in
Trisomy 18
Gene set Supported by literature No evidence
DFLAT 37.8% (14) 62.2% (23)
GOA 31.3% (5) 68.8% (11)
Percent (number) of GO terms from the first two rows of Table 2 that were
found to have independent corroborating evidence in the literature.
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cell differentiation, Photoreceptor cell development), uro-
genital tract (Renal tubule development, Ureter develop-
ment, Prostate gland growth, Collecting duct development),
and muscle (Regulation of striated muscle development,
Myotube development, Muscle adaptation). All of these
were supported by literature. The results of the GOA-only
analysis, while implicating some of the same organ sys-
tems, tended to highlight broader gene sets or earlier
stages of development (e.g., Embryonic camera-type eye
development, Heart looping, Mesonephros development).
That said, there were some informative and probably cor-
rect terms that were significant in the GOA-only analysis
but not the DFLAT analysis, including Glial cell differen-
tiation, Spermatogenesis, and Positive regulation of bio-
mineral tissue development.
There is less literature describing the trisomy 18 pheno-
type, so it is not surprising that fewer Gene Ontology
terms from either collection garnered literature support in
the trisomy 18 analysis. However, many of those that were
identified seem plausible. For example, Regulation of car-
diac muscle cell differentiation and Atrioventricular valve
development were identified in the DFLAT analysis, con-
sistent with the observation that heart defects are com-
mon in trisomy 18 [46], while no significant terms related
to heart development were unique to GOA.
Other molecular processes implicated by these analyses
might form the basis for future studies. Particularly, in
several cases, significantly enriched gene sets represent
processes that seem very likely to be affected in trisomy
18, but direct research would be needed to confirm them.
For example, neural tube defects including spina bifida are
common in patients with trisomy 18 [46,47]. Thus, while
no current research directly links trisomy 18 explicitly
with changes in Spinal cord dorsal/ventral patterning
(a term that appeared significant with DFLAT), future
studies could likely confirm this connection. Similarly, it
would not be unexpected for Axon extension, Schwann
cell development, and Schwann cell differentiation to be
relevant. Several cases of malformed kidneys have also
been described in trisomy 18, and it has been noted that
renal dysplasia deserves further study in this context. Se-
veral kidney-related gene set terms (such as Glomerular
basement membrane and Mesonephric tubule develop-
ment) were identified as significant only with DFLAT.
Though these terms do not have literature support, theyprovide specific testable hypotheses about the trisomy 18
phenotype.
Conclusions
A major contribution of the DFLAT project has been to
capture critical information about developmental context
to further characterize literature-derived functional anno-
tation. The demonstrated impact of this effort on the in-
terpretation of high-throughput molecular data suggests
that ongoing Gene Ontology Consortium efforts to better
model functional contexts will prove valuable.
The five data sets we analyzed here cover a range of de-
velopmental stages, including second-trimester fetuses,
fetuses near term, premature and full-term neonates, and
even infants and toddlers. Yet the DFLAT annotation
appears to implicate additional pathways in the analysis of
all of these data sets. DFLAT’s impact on the analyses of
many different developmental stages is likely due to the
introduction of the orthology-derived annotation, but it
may also reflect the fact that some genes with known roles
in fetal development may continue to play similar roles
after birth. Future work will assess DFLAT’s impact on
analyses of additional pediatric studies. Given the growing
interest in molecular analyses of such pediatric disorders
as autism, ADHD, and asthma, the potential availability of
tools to improve the interpretation of such data would be
quite valuable.
The orthology data used here is based heavily on mouse
models. Recent controversial work on mouse models of
human inflammatory disease has raised questions about
when it is appropriate to rely on data from such models
[48-52]. While anatomical comparisons of developmental
landmarks are well established and generally consistent
between the two organisms [53], there are still some
species-specific differences, as mentioned above in the
Construction and content section. These may very well in-
crease the rate of false positive results. Future work might
mitigate the impact of these differences by incorporating
developmental data from additional vertebrate models
such as rat and zebrafish. In addition, the EMAGE data-
base [27] provides detailed temporospatial information
characterizing expression patterns in the developing
mouse. The possibilities for leveraging these and related
data to further augment the DFLAT collection are intri-
guing. Although the risks of inferring function from ex-
pression are considerable, it might be possible to combine
multiple data sources to do so reliably, potentially yielding
a valuable resource combining molecular and anatomical
data. Ultimately, of course, while functional analyses of ex-
pression data can be greatly helpful in generating or refin-
ing hypotheses, the biological significance of results
obtained through the use of DFLAT – or any functional
enrichment analysis – must be confirmed through further
laboratory experiments.
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http://www.biomedcentral.com/1471-2105/15/45We have focused here on DFLAT’s implications for
gene expression data analysis. However, we emphasize
that the interpretation of sequence variation also often
relies on pre-defined gene sets, and that the integration
of expression and sequence data is a powerful tool for
analyzing the functional interactions of genetic and en-
vironmental factors [54]. The fraction of fetal DNA in
maternal circulation is relatively low [55], but with the
availability of low-cost deep sequencing technologies, it
has become possible to detect fetal aneuploidy reliably
and non-invasively, by comparing the chromosomal dis-
tribution of sequences from maternal blood to the ex-
pected distribution [56]. The recent sequencing of an
entire fetal genome from amniocytes [57], and even from
the cell-free fetal DNA that circulates within maternal
plasma [58] has opened the door to a much larger range
of personalized prenatal diagnostics [57]. It will thus be
valuable to assess the impact of the DFLAT annotation
on the interpretation of fetal genomic sequence as whole
genome DNA sequencing becomes integrated into pre-
natal clinical care.
Overall, DFLAT has added more developmentally fo-
cused human annotation to GOA, providing a useful
tool for researchers studying development in humans. In
particular, DFLAT is well suited for gene set and path-
way analysis on human fetal and neonatal expression
data. Using DFLAT-derived gene sets in gene set enrich-
ment analyses not only provides a larger number of
enriched functions, but provides results that are more
likely to be confirmed in the literature. Even those that
have not yet been confirmed tend to implicate more spe-
cific molecular processes, leading to the development of
novel, focused hypotheses about the molecular mecha-
nisms behind specific pathologies.
Although there is growing evidence of a relationship
between fetal, pediatric, and adult health, little is cur-
rently known about the molecular connections between
neonatal health and later-onset disorders. The DFLAT
annotation augments the infrastructure needed to
analyze developmental gene function. We therefore ex-
pect that future applications of DFLAT annotation will
facilitate the identification of previously-obscured devel-
opmental roles from genomic and clinical data sets, en-
gendering novel insights into developmental impacts on
life-long health.Availability and requirements
All DFLAT annotations and gene sets are freely available
from http://dflat.cs.tufts.edu. The code used to generate
the automated annotation and gene sets can also be
downloaded from this site. Those annotations meeting
Gene Ontology curation standards are also available
through the standard GO releases.Additional files
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providing supporting evidence.
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